

Acute Pericarditis: Rapid Evidence Review

Thomas A. Peterson, MD, and Sean P. Turner, MD, Madigan Army Medical Center Family Medicine Residency Program, Tacoma, Washington; Uniformed Services University of the Health Sciences, Bethesda, Maryland; University of Washington School of Medicine, Seattle, Washington

Katelyn A. Dolezal, MD, Madigan Army Medical Center Family Medicine Residency Program, Tacoma, Washington; Uniformed Services University of the Health Sciences, Bethesda, Maryland

Acute pericarditis is defined as inflammation of the pericardium and occurs in approximately 4.4% of patients who present to the emergency department for nonischemic chest pain, with a higher prevalence in men. Although there are numerous etiologies of pericarditis, most episodes are idiopathic and the cause is presumed to be viral. Diagnosis of pericarditis requires at least two of the following criteria: new or worsening pericardial effusion, characteristic pleuritic chest pain, pericardial friction rub, or electrocardiographic changes, including new, widespread ST elevations or PR depressions. Pericardial friction rubs are highly specific but transient, and they have been reported in 18% to 84% of patients with acute pericarditis. Classic electrocardiographic findings include PR-segment depressions; diffuse, concave, upward ST-segment elevations without reciprocal changes; and T-wave inversions. Transthoracic echocardiography should be performed in all patients with acute pericarditis to characterize the size of effusions and evaluate for complications. Nonsteroidal anti-inflammatory drugs are the first-line treatment option. Glucocorticoids should be reserved for patients with contraindications to first-line therapy and those who are pregnant beyond 20 weeks' gestation or have other systemic inflammatory conditions. Colchicine should be used in combination with first- or second-line treatments to reduce the risk of recurrence. Patients with a higher risk of complications should be admitted to the hospital for further workup and treatment. (Am Fam Physician. 2024;109(5):441-446. Copyright © 2024 American Academy of Family Physicians.)

Acute pericarditis, or inflammation of the pericardium, has numerous etiologies and often produces a characteristic pleuritic chest pain. This article reviews patient-oriented evidence to guide the diagnosis and management of acute pericarditis.

Epidemiology

- In one small study, acute pericarditis was diagnosed in 4.4% of patients admitted to the emergency department with nonischemic chest pain; it accounts for 0.2% of cardiovascular hospital admissions.^{1,2} The exact incidence of acute pericarditis is difficult to estimate because epidemiologic studies are lacking, and mild cases likely resolve without being formally diagnosed.^{3,4}
- Acute pericarditis occurs mostly in adult patients, with a mean age in the 50s.³⁻⁹ Hospital registry data suggest that men are more likely to be affected by acute pericarditis than women, with incidence ratios of 1.7 to 2.0 in men to 1.0 in women.²⁻⁵

- Acute pericarditis is typically a result of systemic disease or related to processes involving the pericardium.^{3,6,9-15} (eTable A).
- Despite advances in diagnostic testing, more than 50% of episodes are idiopathic and the etiology is presumed to be viral.^{3,5} Pericarditis after cardiac injury is emerging as the second leading cause of pericarditis and occurs in 9% to 33% of patients.^{3,5,6,9-14}
- Tuberculosis accounts for up to 70% of pericarditis in endemic areas but is a rare etiology in nonendemic areas.^{9-14,16}

Diagnosis

- Diagnosis of pericarditis requires at least two of the following criteria: new or worsening pericardial effusion, characteristic pleuritic chest pain, pericardial friction rub, or electrocardiographic (ECG) changes, including new, widespread ST elevations or PR depressions.^{6,17}
- Pericarditis can be further classified as acute, incessant, recurrent, or chronic.⁶
- The differential diagnosis includes other causes of acute chest pain, such as thoracic artery aneurysm and dissection, acute coronary syndrome, mediastinitis, pulmonary embolism, pneumonia, pneumothorax, pneumopericardium, costochondritis, gastroesophageal reflux disease, neoplasm, or myocarditis (Table 1).^{6,10,18,19}

Additional content is available with the online version of this article.

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 393.

Author disclosure: No relevant financial relationships.

SIGNS AND SYMPTOMS

- More than 90% of patients being evaluated for acute pericarditis report acute, retrosternal, pleuritic chest pain. Pain may radiate to the jaw, neck, or arms, but this should not be considered sensitive or specific for acute pericarditis.^{6,20,21}
- Pain may be exacerbated by a supine position or improved by leaning forward.⁶ In one cohort study, 46% of patients with pericarditis diagnosed in the emergency department experienced changes in pain with changes in posture.²¹
- Pain is not generally relieved by nitrates.^{6,10,17}
- Patients with an infectious etiology of acute pericarditis may have fever, chills, myalgias, tachycardia, and leukocytosis.^{6,22}
- Pericardial friction rubs are highly specific for pericarditis but have low sensitivity, with 18% to 84% of patients having a pericardial friction rub.^{7,23,24} Friction rub is characterized by a transient, scratchy or squeaky quality that is

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Evaluation of acute pericarditis should include a patient history, physical examination, electrocardiography, chest radiography, transthoracic echocardiography, and baseline laboratory studies. ⁶	C	Expert consensus guidelines
All patients with acute pericarditis should be treated with colchicine (Colcris) and nonsteroidal anti-inflammatory drugs or glucocorticoids to reduce the risk of recurrence. ³⁵⁻³⁸	A	Systematic reviews and meta-analyses with patient-oriented outcomes
Patients with acute pericarditis who have risk factors for serious disease or complications should be hospitalized for further treatment and etiologic workup. ^{6,20}	B	Two prospective cohort studies
Athletes with acute pericarditis should not participate in competitive sports for 3 months after being diagnosed or for 3 to 6 months in those with myopericarditis. ^{6,45}	C	Expert consensus guidelines

A = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

TABLE 1

Differential Diagnosis of Acute Pericarditis and Associated Electrocardiographic Findings

Diagnosis	Symptoms/signs	Electrocardiographic findings	Biomarkers
Acute pericarditis	Retrosternal, sharp, pleuritic chest pain exacerbated by a supine position and relieved by leaning forward; radiation to jaw, arm, or neck; friction rub	PR-segment depression; diffuse, concave ST-segment elevations without reciprocal depressions; T-wave inversion	Troponin elevated in 30% of cases; normal BNP
Myocardial infarction	Crushing, squeezing, retrosternal chest pain; dyspnea; radiation to jaw, arm, or neck	ST-segment elevation, ST-segment depression, T-wave inversion	Troponin elevated; mild elevation of BNP
Myocarditis	Chest pain; dyspnea; signs of heart failure may be present	Nonspecific ST-segment and T-wave changes	Troponin elevated; mild elevation of BNP
Pulmonary embolism	Sharp, stabbing chest pain that may be anterior, posterior, or lateral; may be worse with respiration	Right axis deviation; signs of right ventricular strain (ST-segment depression, T-wave inversion in right precordial leads V ₁ to V ₃)	Troponin and BNP may be elevated in submassive or massive pulmonary embolism; used prognostically

BNP = brain natriuretic peptide.

Information from references 6, 10, 18, and 19.

best auscultated by the patient leaning forward and holding their breath.^{6,10,17,21}

An example of friction rub can be heard at https://www.merckmanuals.com/professional/multimedia/audio/pericardial_friction_rub.

- Acute pericarditis can be complicated by cardiac tamponade, which is suggested by hypotension, pulsus paradoxus, increased jugular venous pressure, and a quiet precordium.⁶

DIAGNOSTIC TESTING

Initial Evaluation

- The initial evaluation should include patient history, physical examination, electrocardiography, chest radiography, transthoracic echocardiography, and baseline laboratory studies (i.e., complete blood count, basic metabolic panel, cardiac biomarkers, erythrocyte sedimentation rate, and serum C-reactive protein levels).⁶
- Classic ECG findings include PR-segment depressions; diffuse, concave, upward ST-segment elevations without reciprocal changes; and T-wave inversions (*Figure 1*).¹⁰ These findings are common but are not present in all cases.^{6,21}
- In contrast, ECG findings suggestive of ischemia or infarction include convex ST elevations that are regional without reciprocal ST depressions. PR depression is generally absent.^{25,26}
- Elevation of C-reactive protein levels occurs in approximately 75% of patients suspected of having acute pericarditis; although it is not diagnostic, elevation can support the diagnosis.²⁷
- In a retrospective observational study, an elevated neutrophil-lymphocyte ratio of 5.0 or greater was associated with an increased probability of recurrence of pericarditis and cardiac tamponade (odds ratio = 2.4; 95% CI, 1.7 to 3.4).²⁸
- Cardiac biomarkers were elevated in 6.4% to 49% of patients in three observational studies.^{21,29,30} In one cohort study, an increase in serum troponin levels was associated with one additional day of hospitalization.³¹
- Chest radiography can detect an enlarged cardiac silhouette, which supports the presence of pericardial effusion.⁶
- Transthoracic echocardiography is recommended for evaluation of patients with acute pericarditis because it can


FIGURE 1

Stage I: Diffuse concave ST-segment elevation

Stage II: ST segments normalize, J point returns to baseline, T-wave amplitude begins to decrease, PR-segment depression begins to appear

Stage III: Symmetrical diffuse T-wave inversions

Stage IV: Changes normalize or T-wave inversions may become permanent



Acute pericarditis electrocardiographic changes, stage I. Diffuse, concave ST-segment elevation and PR-segment depression are best demonstrated in leads I, II, aVL, and V₃ to V₆. Also note ST/T ratio > 0.25 in V₆ (vertical height of ST segment from end of PR segment to J point/amplitude of T wave) and lack of reciprocal ST-segment changes.

Adapted with permission from Snyder MJ, Bepko J, White M. Acute pericarditis: diagnosis and management. *Am Fam Physician*. 2014;89(7):557.


identify potential complications, such as tamponade or constrictive pericarditis.^{10,18}

- Transthoracic echocardiography can indirectly quantify the size of pericardial effusion. Pericardial effusions larger than 21 mm on echocardiography are associated with a higher risk of complications.¹⁸
- In patients with suspected viral pericarditis, routine identification of the causative agent is not recommended unless hepatitis C or HIV infection is suspected.¹⁷

Subsequent Testing for High-Risk or Hospitalized Patients

- For patients who require hospitalization, evaluation should include obtaining blood and pericardial cultures to identify bacterial infections, genomic polymerase chain reaction testing to identify viruses, and antinuclear antibody testing to identify autoimmune conditions.^{6,20}
- Computed tomography and cardiac magnetic resonance imaging are considered adjunct studies that could identify

FIGURE 2



ECG = electrocardiographic; NSAID = nonsteroidal anti-inflammatory drug.

Diagnosis and treatment of acute pericarditis.

Information from references 6 and 20.

pericardial effusion or evidence of myocardial inflammation.¹⁸ In a retrospective observational study, pericardial thickening or enhancement was the most accurate single parameter for pericarditis, with a sensitivity of 54% to 59% and a specificity of 91% to 96% (positive likelihood ratio = 8.1; negative likelihood ratio = 0.46).³²

- Tuberculosis testing using interferon gamma release assay with acid-fast bacilli staining and cultures should be considered in areas where tuberculosis is endemic.^{17,33}

Treatment

- First-line treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine (Colcrys), and a proton pump inhibitor for gastroprotection. Ibuprofen and indomethacin are the most commonly used NSAIDs; aspirin is preferred in patients with comorbid coronary artery disease.^{6,34}

- Expert opinion suggests that NSAIDs should be used for 7 to 10 days followed by a gradual taper once symptoms improve and C-reactive protein levels normalize.²⁷

- Glucocorticoids are typically second-line therapy or used when NSAIDs are contraindicated (e.g., beyond 20 weeks' gestation, systemic inflammatory disease) due to a higher risk of recurrence and adverse effects. Prednisone dosages of 0.25 to 0.5 mg per kg per day followed by a slow taper minimize the risk of recurrence compared with higher dosages.⁶

- The addition of colchicine to first- or second-line agents significantly reduces the recurrence rate of acute pericarditis (absolute risk reduction = 22%; number needed to treat = 5) and recurrent pericarditis (absolute risk reduction = 23%; number needed to treat = 4). Colchicine should be used for 3 months in patients with acute pericarditis and at least 6 months in those with recurrent pericarditis.³⁵⁻³⁸

- Triple therapy with NSAIDs, glucocorticoids, and colchicine may be used in patients with recurrent pericarditis refractory to standard care, based on expert opinion and an observational study. If symptoms recur during glucocorticoid tapering, it is preferred to restart by increasing the dosage of the NSAID, not increasing the dosage of the glucocorticoid.^{6,39,40}

- Use of anti-interleukin-1 agents, such as anakinra and rilonacept (Arcalyst), for the treatment

of recurrent pericarditis refractory to standard treatment is supported by two small randomized controlled trials. A retrospective cohort study and a systematic review show weaker evidence for the use of azathioprine and intravenous immune globulin, respectively.^{6,41-44}

- Pericardiocentesis may be performed for cardiac tamponade, for suspected bacterial or neoplastic etiology, or for symptomatic effusions that have not responded to standard therapy.⁶
- Major risk factors derived from multivariate analysis and minor risk factors derived from expert opinion are associated with a worse prognosis and should prompt consideration for hospital admission and further workup (Figure 2).^{6,20}
- Based on expert opinion, athletes should not participate in competitive sports for 3 months after the diagnosis of acute pericarditis and 3 to 6 months if there is myopericarditis. It is reasonable to return to play in less time if serum biomarkers, left ventricular function, and ECG findings have normalized.^{6,45}

Prognosis

- Mortality in acute pericarditis is low, with a rate of 1.1% in hospitalized patients.²
- Idiopathic pericarditis is generally self-limited and responds well to initial treatment within a few days. Less than 5% of patients experience poor symptom resolution with initial treatment.^{6,35,37}
- Symptoms recur in 10% to 30% of patients despite an initial satisfactory response to treatment with an NSAID and colchicine.^{35,37,46}
- Significant complications can include pericardial effusion causing cardiac tamponade, left ventricular dysfunction, arrhythmias, heart failure, and constrictive pericarditis.^{6,47}
- Although patients with idiopathic recurrent pericarditis experience higher morbidity, serious late complications, including tamponade, left ventricular dysfunction, and constrictive pericarditis, are rare.^{40,47,48}

This article updates previous articles on this topic by Snyder, et al.¹⁰; Tingle, et al.⁴⁹; Goyle and Walling⁵⁰; and Marinella.⁵¹

Data Sources: A PubMed search was completed in Clinical Queries using the key term pericarditis. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Essential Evidence Plus, POEMs, the Cochrane database, DynaMed, and UpToDate were also searched. Whenever possible, if studies used race and/or gender as patient categories but did not define how these categories were assigned, they were not included in our final review. If studies using these categories were determined to be essential and were therefore included, limitations were explicitly stated in the manuscript. Search dates: April, June, and November 2023, and March 2024.

The views expressed are those of the authors and do not reflect the official policy of the Madigan Army Medical Center, Uniformed

Services University of the Health Sciences, U.S. Department of the Army, U.S. Department of Defense, or U.S. government.

The Authors

THOMAS A. PETERSON, MD, is residency faculty at the Madigan Army Medical Center Family Medicine Residency Program, Tacoma, Wash.; an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md.; and a clinical instructor in the Department of Family Medicine at the University of Washington School of Medicine, Seattle.

SEAN P. TURNER, MD, is residency faculty at the Madigan Army Medical Center Family Medicine Residency Program, an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, and a clinical instructor in the Department of Family Medicine at the University of Washington School of Medicine.

KATELYN A. DOLEZAL, MD, is associate program director of the Madigan Army Medical Center Family Medicine Residency Program and an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences.

Address correspondence to Thomas A. Peterson, MD, Madigan Army Medical Center, 9040 Jackson Ave., Joint Base Lewis-McChord, WA 98431 (thomas.a.peterson86.mil@health.mil). Reprints are not available from the authors.

References

1. Fruergaard P, Launbjerg J, Hesse B, et al. The diagnoses of patients admitted with acute chest pain but without myocardial infarction. *Eur Heart J*. 1996;17(7):1028-1034.
2. Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. *Circulation*. 2014;130(18):1601-1606.
3. Gouret F, Levy PY, Casalta JP, et al. Etiology of pericarditis in a prospective cohort of 1162 cases. *Am J Med*. 2015;128(7):784.e1-784.e8.
4. Kumar N, Pandey A, Jain P, et al. Acute pericarditis-associated hospitalization in the USA: a nationwide analysis, 2003-2012. *Cardiology*. 2016;135(1):27-35.
5. Vecchiè A, Chiabrando JG, Dell MS, et al. Clinical presentation and outcomes of acute pericarditis in a large urban hospital in the United States of America. *Chest*. 2020;158(6):2556-2567.
6. Adler Y, Charron P, Imazio M, et al.; ESC Scientific Document Group. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2015;36(42):2921-2964.
7. Imazio M, Demicheli B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. *J Am Coll Cardiol*. 2004;43(6):1042-1046.
8. Imazio M, Cecchi E, Demicheli B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. *Heart*. 2008;94(4):498-501.
9. Shakti D, Hehn R, Gauvreau K, et al. Idiopathic pericarditis and pericardial effusion in children: contemporary epidemiology and management. *J Am Heart Assoc*. 2014;3(6):e001483.
10. Snyder MJ, Bepko J, White M. Acute pericarditis: diagnosis and management. *Am Fam Physician*. 2014;89(7):553-560.

11. Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. *Am J Cardiol*. 1995;75(5):378-382.
12. Levy PY, Fournier PE, Charrel R, et al. Molecular analysis of pericardial fluid: a 7-year experience. *Eur Heart J*. 2006;27(16):1942-1946.
13. Fallek Boldes O, Dahan S, Segal Y, et al. Characteristics of pericardial biopsy: 100 cases in a single center. *Isr Med Assoc J*. 2019;21(3):183-188.
14. Sathirareungchai S, Kobayashi M, Shimizu D. Etiologies of pericarditis in hospital and forensic autopsies. *Cardiovasc Pathol*. 2020;49:107262.
15. Ariyaratnam V, Spodick DH. Acute pericarditis: diagnostic cues and common electrocardiographic manifestations. *Cardiol Rev*. 2007;15(1):24-30.
16. Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large academic hospital in South Africa. *Epidemiol Infect*. 2005;133(3):393-399.
17. Lazarou E, Tsioufis P, Vlachopoulos C, et al. Acute pericarditis: update. *Curr Cardiol Rep*. 2022;24(8):905-913.
18. Chiabrando JG, Bonaventura A, Vecchiè A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. *J Am Coll Cardiol*. 2020;75(1):76-92.
19. Henzler T, Roeger S, Meyer M, et al. Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction. *Eur Respir J*. 2012;39(4):919-926.
20. Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. *Circulation*. 2010;121(7):916-928.
21. Hooper AJ, Celenza A. A descriptive analysis of patients with an emergency department diagnosis of acute pericarditis. *Emerg Med J*. 2013;30(12):1003-1008.
22. Radovanovic M, Petrovic M, Hanna RD, et al. Clinical presentation and management of methicillin-resistant *Staphylococcus aureus* pericarditis-systematic review. *J Cardiovasc Dev Dis*. 2022;9(4):103.
23. Spodick DH. Pericardial rub. Prospective, multiple observer investigation of pericardial friction in 100 patients. *Am J Cardiol*. 1975;35(3):357-362.
24. Prepoudis A, Koechlin L, Nestelberger T, et al.; APACE investigators. Incidence, clinical presentation, management, and outcome of acute pericarditis and myopericarditis. *Eur Heart J Acute Cardiovasc Care*. 2022;11(2):137-147.
25. Spodick DH. Diagnostic electrocardiographic sequences in acute pericarditis. Significance of PR segment and PR vector changes. *Circulation*. 1973;48(3):575-580.
26. Ginzton LE, Laks MM. The differential diagnosis of acute pericarditis from the normal variant: new electrocardiographic criteria. *Circulation*. 1982;65(5):1004-1009.
27. Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. *Circulation*. 2011;123(10):1092-1097.
28. Yilmaz F, Yilmaz FK, Karagöz A, et al. Usefulness of neutrophil-to-lymphocyte ratio for predicting acute pericarditis outcomes. *Acta Cardiol*. 2022;77(5):422-430.
29. Imazio M, Demicheli B, Cecchi E, et al. Cardiac troponin I in acute pericarditis. *J Am Coll Cardiol*. 2003;42(12):2144-2148.
30. Bonnefoy E, Godon P, Kirkorian G, et al. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. *Eur Heart J*. 2000;21(10):832-836.
31. Machado S, Roubille F, Gahide G, et al. Can troponin elevation predict worse prognosis in patients with acute pericarditis? *Ann Cardiol Angeiol (Paris)*. 2010;59(1):1-7.
32. Hammer MM, Raptis CA, Javidan-Nejad C, et al. Accuracy of computed tomography findings in acute pericarditis. *Acta Radiol*. 2014;55(10):1197-1202.
33. Cremer PC, Kumar A, Kontzias A, et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. *J Am Coll Cardiol*. 2016;68(21):2311-2328.
34. Lexicomp. Wolters Kluwer; 2023. Accessed May 4, 2023. <https://www.wolterskluwer.com/en/solutions/lexicomp>
35. Imazio M, Brucato A, Belli R, et al. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014—systematic review and meta-analysis. *J Cardiovasc Med (Hagerstown)*. 2014;15(12):840-846.
36. Alabed S, Cabello JB, Irving GJ, et al. Colchicine for pericarditis. *Cochrane Database Syst Rev*. 2014;(8):CD010652.
37. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. *Lancet*. 2014;383(9936):2232-2237.
38. Imazio M, Brucato A, Forno D, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. *Heart*. 2012;98(14):1078-1082.
39. Imazio M, Lazaros G, Brucato A, et al. Recurrent pericarditis: new and emerging therapeutic options. *Nat Rev Cardiol*. 2016;13(2):99-105.
40. Brucato A, Brambilla G, Moreo A, et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. *Am J Cardiol*. 2006;98(2):267-271.
41. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. *JAMA*. 2016;316(18):1906-1912.
42. Klein AL, Imazio M, Cremer P, et al.; RHAPSODY Investigators. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. *N Engl J Med*. 2021;384(1):31-41.
43. Vianello F, Cinetto F, Cavarro M, et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. *Int J Cardiol*. 2011;147(3):477-478.
44. Imazio M, Lazaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. *J Cardiovasc Med (Hagerstown)*. 2016;17(4):263-269.
45. Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). *Eur Heart J*. 2019;40(1):19-33.
46. Imazio M, Brucato A, Cemin R, et al.; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. *N Engl J Med*. 2013;369(16):1522-1528.
47. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. *Circulation*. 2011;124(11):1270-1275.
48. Imazio M, Brucato A, Adler Y, et al. Prognosis of idiopathic recurrent pericarditis as determined from previously published reports. *Am J Cardiol*. 2007;100(6):1026-1028.
49. Tingle LE, Molina D, Calvert CW. Acute pericarditis. *Am Fam Physician*. 2007;76(10):1509-1514.
50. Goyle KK, Walling AD. Diagnosing pericarditis. *Am Fam Physician*. 2002;66(9):1695-1702.
51. Marinella MA. Electrocardiographic manifestations and differential diagnosis of acute pericarditis. *Am Fam Physician*. 1998;57(4):699-704.

eTABLE A

Etiologies of Acute Pericarditis

Acute/idiopathic	Infectious	Infectious (continued)	Noninfectious (continued)
Drug related	Bacterial	Viral	Neoplasms
Antineoplastic drugs (e.g., cyclophosphamide, cytarabine, daunorubicin, doxorubicin, fluorouracil)	<i>Actinomyces neuui</i>	Adenoviruses	Primary tumors (e.g., fibroma, lipoma, meso- thelioma, pericardial cardiac angiosarcoma)
Bromocriptine (Parlodel)	<i>Borrelia burgdorferi</i>	Enteroviruses (e.g., cox- sackievirus, echovirus)	Secondary tumors (e.g., adenocarcinoma of the breast, colon, cystic duct, kidney, liver, and lung; bladder carcinoma; chol- angiocarcinoma; gastric carcinoma; leukemia; lymphoma; mediastinal sarcoma; melanoma; mesothelioma; myeloma; ovarian tumor; papillary thyroid carcinoma; renal cell carcinoma; small cell lung carcinoma; squamous cell uterine carcinoma)
Clozapine	<i>Chlamydia</i> spp.	Hepatitis A, B, and C	
Cyclosporine	<i>Coxiella burnetii</i>	Herpesviruses (e.g., cyto- megalovirus, Epstein-Barr virus, human herpesvirus type 6, varicella-zoster virus)	
Dantrolene (Dantrium)	<i>Haemophilus</i> spp.	HIV	
Granulocyte-macrophage colony-stimulating factor	<i>Klebsiella</i>	Influenza	
Lupus-like syndrome (e.g., hydralazine, isoniazid, methyldopa, phenytoin, procainamide)	<i>pneumoniae</i>	Parainfluenza	
Mesalamine	<i>Legionella</i> spp.	Parvovirus B19	
Methysergide	<i>Leptospira</i> spp.	Other	
Minoxidil	<i>Listeria</i> spp.	<i>Echinococcus</i> spp.	
<i>para</i> -aminosalicylic acid	<i>Mycobacterium</i>	Löffler syndrome	
Penicillins	<i>tuberculosis</i>	<i>Toxoplasma</i> spp.	
Practolol	<i>Mycoplasma</i> spp.		
Some vaccines	<i>Neisseria</i>		
Streptomycin	<i>meningitidis</i>		
Sulfa drugs	<i>Photobacterium</i>		
Thiazides	<i>damselae</i>		
Thiouracils	<i>Providencia stuartii</i>		
Tumor necrosis factor inhibitors	<i>Pseudomonas</i>		
Metabolic	<i>aeruginosa</i>		
Anorexia nervosa	<i>Salmonella</i> spp.		
Myxedema	<i>Staphylococcus</i> spp.		
Uremia	<i>Streptococcus</i> spp.		
Other	<i>Syphilis</i> spp.		
Dissecting aortic aneurysm	<i>Tropheryma</i>		
Heart failure	<i>whipplei</i>		
Pulmonary arterial hypertension	Fungal		
	<i>Aspergillus</i> spp.		
	<i>Blastomyces</i> spp.		
	<i>Candida</i> spp.		
	<i>Coccidioides</i> spp.		
	<i>Cryptococcus</i> spp.		
	<i>Histoplasma</i> spp.		

Information from:

Adler Y, Charron P, Imazio M, et al.; ESC Scientific Document Group. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964.

Ariyaratna V, Spodick DH. Acute pericarditis: diagnostic cues and common electrocardiographic manifestations. Cardiol Rev. 2007;15(1):24-30.

Fallek Boldes O, Dahan S, Segal Y, et al. Characteristics of pericardial biopsy: 100 cases in a single center. Isr Med Assoc J. 2019;21(3):183-188.

Gouriet F, Levy PY, Casalta JP, et al. Etiology of pericarditis in a prospective cohort of 1162 cases. Am J Med. 2015;128(7):784.e1-784.e8.

Levy PY, Fournier PE, Charrel R, et al. Molecular analysis of pericardial fluid: a 7-year experience. Eur Heart J. 2006;27(16):1942-1946.

Sathirareuangchai S, Kobayashi M, Shimizu D. Etiologies of pericarditis in hospital and forensic autopsies. Cardiovasc Pathol. 2020;49:107262.

Shakti D, Hehn R, Gauvreau K, et al. Idiopathic pericarditis and pericardial effusion in children: contemporary epidemiology and management. J Am Heart Assoc. 2014;3(6):e001483.

Snyder MJ, Bepko J, White M. Acute pericarditis: diagnosis and management. Am Fam Physician. 2014;89(7):553-560.

Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol. 1995;75(5):378-382.